Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Aug 09, 2018 3:49pm

147 Views

Post# 28435789

RE:RE:RE:Manipulation

We need a few more Q's. We need Trogarzo to start to impact the bottom line. We need to hit 500 patients or 1000 patients to start to see the reality of this opportunity. We have to think like an ignorant market that hasnt even started doing its homework on this stock yet. We need patience. We need to ignore the noise now and be focused on late 2018 and beyond.

(or not do any of those things.)

Bullboard Posts

How one company is disrupting PoC testing